Tag Archives: half

ASCO: AZ, Merck’s Lynparza fends off pancreatic cancer, cutting progression risk in half

CHICAGO—AstraZeneca and Merck’s Lynparza is on a roll when it comes to making headlines at the American Society of Clinical Oncology annual meeting—and doing it in some of the toughest-to-treat cancers out there. And it wasn’t going to stop this year. Sunday, the drugmakers trumpeted phase 3 data showing the PARP inhibitor slashed the risk… Read More »

Scientists create drug cocktail to cut treatment time by half for resistant tuberculosis

A new drug cocktail reduces the length of treatment for multidrug-resistant tuberculosis from nearly two years to nine to 11 months with a similar effectiveness, according to a large clinical trial whose results were published in a U.S. journal Wednesday. Nearly 600,000 people contract multidrug-resistant tuberculosis (MDR-TB) every year, killing more people than any other… Read More »